Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:LNW News 12 January 2026

Australian stock market today: ASX 200 rises on spending jump as Light & Wonder leaps on Aristocrat deal

Australian stock market today: ASX 200 rises on spending jump as Light & Wonder leaps on Aristocrat deal

The ASX 200 closed up 0.48% at 8,759.4, led by gains in consumer and financial stocks. Light & Wonder surged nearly 18% after settling a lawsuit with Aristocrat for $127.5 million. Super Retail Group fell about 6% after warning first-half profits would miss last year’s results. Household spending rose 1% in November, official data showed.
12 January 2026
····

Stock Market Today

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

7 February 2026
New York, Feb 7, 2026, 09:34 EST — Market closed. Alphabet’s non-voting Class C shares (GOOG) closed down 2.48% at $323.10 on Friday, extending a pullback after the Google parent flagged a sharp jump in spending tied to artificial intelligence. (Reuters) With U.S. markets shut for the weekend, the near-term test is whether investors keep treating Big Tech’s AI build-out as a cost problem before it becomes a growth story. A Reuters review of the week’s trading showed fresh jitters around 2026 outlays across the sector, and SanJac Alpha chief investment officer Andrew Wells said the AI trade “got too
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop